
Wyeth finds itself in the #12 spot of 15 for research and development budget with $2.35 bn EUR and #10 in overall sales for 2006.
2007 was a tough year for the company as its 3 big drug candidates, bifeprunox, an antipsychotic, HCV-796, a hepatitis C drug and Pristiq, a major depressivePending approval:
PhasePristiq - Major depressive disorder
Bifeprunox - schizophrenia
Lybrel - Continuous contraception
Viviant - Postmenopausal osteoporosis
Pristiq - Vasomotor symptoms of menopause
Torisel - Renal cell carcinomaIII [Source: FierceBiotech]






» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 14, 2007 2:18 PM | Permalink to Trackback